A5100670860- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Advanced Breast Cancer Therapies
- Nonmelanoma Skin Cancer Studies
- Renal and related cancers
- Ferroptosis and cancer prognosis
- Esophageal Cancer Research and Treatment
- Atherosclerosis and Cardiovascular Diseases
- Parkinson's Disease Mechanisms and Treatments
- Brain Metastases and Treatment
- Cancer Cells and Metastasis
- Traditional Chinese Medicine Analysis
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Cell Adhesion Molecules Research
- Multiple and Secondary Primary Cancers
- Neurological disorders and treatments
- Peptidase Inhibition and Analysis
Peking University
2016-2025
Peking University Cancer Hospital
2016-2025
University of Michigan–Ann Arbor
2018-2025
Capital Medical University
2022-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2017-2024
Xiyuan Hospital
2017-2024
Guang’anmen Hospital
2024
Tsinghua University
2023
Novartis (Switzerland)
2023
Bioscience (China)
2023
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory either therapy alone.We conducted a single-center, phase IB trial evaluating safety preliminary efficacy toripalimab, humanized immunoglobulin G4 monoclonal...
Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal has not been established. We conducted a randomized phase II clinical trial in patients resected to compare the efficacy safety of high-dose IFN-α2b (HDI) temozolomide-based chemotherapy as therapy.Patients stage II/III after surgery were into three groups: observation group (group A, alone), HDI B, treated 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 U IFN-α2b), temozolomide...
JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate safety, tolerability, clinical activity JS001 advanced melanoma or urologic cancer patients who are refractory standard systemic therapy. In dose escalation cohorts, subjects initially received single-dose, intravenous infusion were followed for 28 days by...
Purpose: Effective therapies for the majority of metastatic acral melanoma patients have not been established. Thus, we investigated genetic aberrations CDK4 pathway in and evaluated efficacy CDK4/6 inhibitors targeted therapy melanoma.Experimental Design: A total 514 primary samples were examined copy number variations (CNV) pathway-related genes, including Cdk4, Ccnd1, P16INK4a , by QuantiGenePlex DNA Assay. The sensitivity established cell lines patient-derived xenograft (PDX) containing...
Background: Exosomes in cardiovascular diseases (CVDs) have become an active research field with substantial value and potential. Nevertheless, there are few bibliometric studies this field. We aimed to visualize the hotspots trends of exosomes CVDs using a analysis help understand future development basic clinical research. Methods: The articles reviews regarding were culled from Web Science Core Collection, knowledge maps generated CiteSpace VOSviewer software. Results: A total 1,039...
Mucosal melanoma is an aggressive subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination toripalimab, a humanized IgG4 mAb against PD-1, showed promising rate patients metastatic mucosal (MM) phase Ib study. Here, we report the updated overall survival (OS), duration of (DoR), and biomarker analysis results.Patients advanced MM received toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined axitinib 5 mg orally two times per day until...
Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination carboplatin plus paclitaxel (CPB) patients previously untreated advanced MM.Patients were randomly assigned 2:1 ratio to receive (area under curve, 5) (175 mg/m2) once every 4 weeks (CPB arm, 5 mg/kg) or without (CP arm) 2 weeks. Progression-free survival (PFS) was primary end point....
515 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC), which showed promising data in HER2-positive and even negative patients (pts) with metastatic urothelial carcinoma (mUC). Toripalimab an anti-PD-1 antibody durable antitumor effect for mUC. The combination may have synergistic effect. Initial RC48-C014 was previously presented (ASCO 2021); here we reported update on safety ORR. Methods: In dose-escalation cohort, pts received 1.5 or 2 mg/kg + 3mg/kg...
<h3>Background/objective</h3> In patients with conjunctival melanomas, surgery is the first choice of treatment, but no standard adjuvant therapy has been established. this study, we evaluated prognostic factors for melanoma in ethnic Chinese patients. <h3>Methods</h3> Demographic data, known (published) factors, BRAF and KIT gene mutations, treatment strategies outcomes were reviewed 53 pathologically confirmed melanomas. Univariate multivariate analyses associated survival performed by...
Background: Tanshinone IIA (Tan IIA), a lipophilic constituent from Salvia miltiorrhiza Bunge, has shown promising cardioprotective effect including anti-atherosclerosis. This study aims at exploring Tan IIA's anti-inflammatory and immune-regulating roles in stabilizing vulnerable atherosclerotic plaque ApoE-deficient (ApoE-/-) mice. Methods: Male ApoE-/- mice (6 weeks) were fed with high-fat diet for 13 weeks then randomized to the model group (MOD) or groups [high dose: 90 mg/kg/day (HT),...
Neuregulins (NRGs) are emerging as an important family of signaling ligands that regulate glucose and lipid homeostasis. NRG1 lowers blood levels in obese mice, whereas the brown fat–enriched secreted factor NRG4 protects mice from high-fat diet–induced insulin resistance hepatic steatosis. However, therapeutic potential NRGs remains elusive, given poor plasma half-life native ligands. Here, we engineered a fusion protein using human Fc domain IgG1 (NRG1-Fc) exhibited extended circulation...
4519 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC). A phase II clinical study showed that has good effect on locally advanced or metastatic urothelial carcinoma with HER2-positive expression failed standard chemotherapy. In the study, some patients HER2-postive immunohistochemistry (IHC 2+) but negative FISH test still benefited from treatment of RC48-ADC.This was to evaluate activity and safety in HER2-negative carcinoma. Methods: This an open-label,...
The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. alteration correlates with aggressive disease cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits patients advanced urothelial carcinoma .The information on pathologically proven detected status was collected from the database Peking University Cancer Hospital. expression, well its association characteristics and prognosis, analyzed.A total 284 consecutive were enrolled. positive...
4566 Background: Disitamab vedotin has shown promising data across a spectrum of HER2 expression in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who progressed on chemotherapy. This study was conducted to evaluate the safety and efficacy disitamab plus anti-PD-1 antibody carcinoma. Methods: is an open-label, multicenter, phase 1b/2 trial activity RC48-ADC combined toripalimab, humanized immunoglobin G 4 monoclonal against PD-1 mUC. Patients received at 1.5 2...
Background OH2 is an oncolytic virus derived from herpes simplex type 2. A phase Ia/Ib clinical trial in China was conducted patients with unresected stage III–IV melanoma, the majority of whom had acral type, to assess safety and preliminary efficacy OH2. Methods The enrolled histologically confirmed unresectable III or advanced IV melanoma. In Ia, nine received single-dose treatment across three dose levels (10 6 , 10 7 8 CCID 50 /mL, where represents cell culture infectious 50%) while six...
Immune checkpoint inhibitors (ICIs) have provided new hope for melanoma patients, however, not all patients benefit. Furthermore, ICI-related therapies cause significant immune-related adverse events that adversely affect patient outcomes. Therefore, there is a pressing need reliable biomarkers to identify most likely benefit from these treatments. In this study, we employed an extracellular vesicles (EVs) protein expression array explore the longitudinal membrane profiles of plasma-derived...
Abstract Background The incidence of renal cell cancer (RCC) has been increasing for the past decade, and 5-year survival patients with metastatic RCC (mRCC) is rather low. Everolimus (RAD001), a new inhibitor mammalian target rapamycin (mTOR), generally well tolerated, demonstrates clinical benefit to anti-VEGF-refractory mRCC. However, factors selection who may from everolimus remain largely unknown. Here we aimed explore potential molecular indicators mRCC treatment. Methods...